NCT04531020

Brief Summary

Emergence delirium (ED) is serious complication in the postoperative period in paediatric anaesthesia, reported incidence is 20-60%. It is characterized by psychomotor and perception disorder with excitation of paediatric patients. Emergence delirium has impact on morbidity and even on mortality of paediatric patients in the postoperative period. The potential risk factors for ED development include sevoflurane, which is the dominant anaesthetic agent used in the paediatric patients, and which is actually the only inhalation agent used for inhalation anaesthesia induction. The incidence of ED is higher in postoperative period, for example in the Post-anaesthesia Care Unit - PACU. Patients with ED are at higher risk of psychomotor anxiety, agitation, unintentional extraction of intravenous cannula, and nausea and vomiting. For the therapy of ED propofol, midazolam and eventually ketamine in a reduced dosage are used.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,421

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Oct 2020

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 21, 2020

Completed
7 days until next milestone

First Posted

Study publicly available on registry

August 28, 2020

Completed
1 month until next milestone

Study Start

First participant enrolled

October 1, 2020

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2021

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2022

Completed
Last Updated

February 15, 2022

Status Verified

February 1, 2022

Enrollment Period

9 months

First QC Date

August 21, 2020

Last Update Submit

February 14, 2022

Conditions

Keywords

Emergence deliriumAnaesthesiaPaediatric patient

Outcome Measures

Primary Outcomes (1)

  • The incidence of emergence delirium

    The incidence of emergence delirium, defined as PAED score above 10 points and/or WATCHA score over 2 and or RASS over 1 minimally in one of the measurements. All measurements will be measured in 0., 5., 10., 15., and 20. minute after PACU admission. The first measurement (T0) will be intiated after first obtaining RASS over -2.

    up to 60 minutes after PACU admission

Secondary Outcomes (11)

  • The duration of ED

    up to 60 minutes after PACU admission

  • The average PAED score

    up to 60 minutes after PACU admission

  • The need for pharmacology intervention incidence

    up to 60 minutes after PACU admission

  • incidence of postoperative nausea and vomiting (PONV)

    up to 60 minutes after PACU admission

  • type of anaesthesia induction (inhalation vs. intravenous)

    up to 60 minutes after PACU admission

  • +6 more secondary outcomes

Study Arms (1)

Patients at PACU

Patients undergoing elective surgical or diagnostic intervention admitted to PACU after postanaesthesia recovery

Diagnostic Test: PAED measurement

Interventions

PAED measurementDIAGNOSTIC_TEST

The incidence of emergence delirium, defined as PAED score above 10 points minimally in one of the PAED score measurements. PAED score will be measured in 0., 5., 10., 15., and 20. minute after PACU admission.

Also known as: PAED score measurement at PACU
Patients at PACU

Eligibility Criteria

Age1 Month - 19 Years
Sexall
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Patients after general anaesthesia hospitalized in the PACU

You may qualify if:

  • Patients after general anaesthesia hospitalized in the PACU in the term rom 1.9.2020 until 30.6.2021.

You may not qualify if:

  • Patients in the age from 0 to 1 month.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital Brno

Brno, Česká Republika, 62500, Czechia

Location

MeSH Terms

Conditions

Emergence Delirium

Condition Hierarchy (Ancestors)

DeliriumConfusionNeurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesPostoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsSigns and SymptomsNeurocognitive DisordersMental Disorders

Study Officials

  • Petr Štourač, prof. MD., Ph.D.

    Faculty of medicince Masaryk University and University Hospital Brno

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Professor

Study Record Dates

First Submitted

August 21, 2020

First Posted

August 28, 2020

Study Start

October 1, 2020

Primary Completion

June 30, 2021

Study Completion

January 1, 2022

Last Updated

February 15, 2022

Record last verified: 2022-02

Locations